Mara Goldstein
Stock Analyst at Mizuho
(2.47)
# 2,383
Out of 5,123 analysts
70
Total ratings
47.17%
Success rate
12.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $410 → $600 | $20.15 | +2,877.67% | 2 | Jan 27, 2026 | |
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $7.40 | +305.41% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.36 | +323.73% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $6.28 | +27.39% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $20.03 | +109.69% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $10.82 | +362.11% | 2 | Jan 22, 2024 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $102.76 | -25.07% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $11.88 | -41.08% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.05 | +661.90% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $35.12 | +156.26% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $19.06 | -81.64% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.90 | +18,847.37% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $4.52 | +342.48% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $119.75 | +8.56% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $5.24 | -61.83% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.32 | +809.09% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $60.24 | -66.80% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $11.13 | +331.27% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.58 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $7.00 | +100.00% | 1 | Oct 12, 2017 |
Syndax Pharmaceuticals
Jan 27, 2026
Maintains: Outperform
Price Target: $410 → $600
Current: $20.15
Upside: +2,877.67%
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $7.40
Upside: +305.41%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.36
Upside: +323.73%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.28
Upside: +27.39%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $20.03
Upside: +109.69%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $10.82
Upside: +362.11%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $102.76
Upside: -25.07%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $11.88
Upside: -41.08%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.05
Upside: +661.90%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $35.12
Upside: +156.26%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $19.06
Upside: -81.64%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.90
Upside: +18,847.37%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $4.52
Upside: +342.48%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $119.75
Upside: +8.56%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $5.24
Upside: -61.83%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.32
Upside: +809.09%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $60.24
Upside: -66.80%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $11.13
Upside: +331.27%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $22.58
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $7.00
Upside: +100.00%